Methodological issues of human experimental research with hallucinogens

被引:12
作者
Gouzoulis-Mayfrank, G
Schneider, F
Friedrich, J
Spitzer, M
Thelen, B
Sass, H
机构
[1] Rhein Westfal TH Aachen, Klin Psychiat & Psychotherapie, Dept Psychol & Psychotherapy, D-52074 Aachen, Germany
[2] Univ Dusseldorf, Dept Psychiat, D-4000 Dusseldorf, Germany
[3] Tech Univ Darmstadt, Dept Psychol, Darmstadt, Germany
[4] Univ Ulm, Dept Psychiat, D-89069 Ulm, Germany
关键词
D O I
10.1055/s-2007-979356
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human experimental research with hallucinogenic drugs is potentially able to identify linking variables between the psycho(patho)logical conditions and neurobiological alterations involved in both pharmacologically induced and naturally occurring acute psychotic states. A number of methodological aspects should be considered when planning modern experimental studies with hallucinogenic drugs. The issues of subject selection, repeated measures, and adequate control groups are discussed in this paper. Examples of recent experimental studies are presented which take these aspects into account. The first study examined psychopathological changes, facial expression and semantic priming effects during a psilocybin-induced state. In the second study, semantic priming effects after intake of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE), and d-methamphetamine were investigated. Results confirmed time-dependent effects of psilocybin and the restriction of increased priming effects in the psilocybin group.
引用
收藏
页码:114 / 118
页数:5
相关论文
共 21 条
[1]   The NMDA antagonist model for schizophrenia: Promise and pitfalls [J].
Abi-Saab, WM ;
D'Souza, DC ;
Moghaddam, B ;
Krystal, JH .
PHARMACOPSYCHIATRY, 1998, 31 :104-109
[2]   PSYCHOPHARMACOLOGY NEED FOR LINKING VARIABLES [J].
CALLAWAY, E .
BIOLOGICAL PSYCHIATRY, 1992, 31 (01) :1-3
[3]   History, rationale and potential of human experimental hallucinogenic drug research in psychiatry [J].
Gouzoulis-Mayfrank, E ;
Hermle, L ;
Thelen, B ;
Sass, H .
PHARMACOPSYCHIATRY, 1998, 31 :63-68
[4]  
GouzoulisMayfrank E, 1996, NERVENARZT, V67, P369
[5]  
Grob CS, 1996, BEHAV BRAIN RES, V73, P103
[6]  
HEIMANN H, 1961, PSYCHIAT NEUROL, V141, P69
[7]   Blood flow and cerebral laterality in the mescaline model of psychosis [J].
Hermle, L ;
Gouzoulis-Mayfrank, E ;
Spitzer, M .
PHARMACOPSYCHIATRY, 1998, 31 :85-91
[8]  
OVERALL JE, 1962, PSYCHOL REP, V10, P799
[9]   COMPUTER-BASED ANALYSIS OF FACIAL ACTION IN SCHIZOPHRENIC AND DEPRESSED-PATIENTS [J].
SCHNEIDER, F ;
HEIMANN, H ;
HIMER, W ;
HUSS, D ;
MATTES, R ;
ADAM, B .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1990, 240 (02) :67-76
[10]   THE EFFECTS OF NEUROLEPTICS ON FACIAL ACTION IN SCHIZOPHRENIC-PATIENTS [J].
SCHNEIDER, F ;
ELLGRING, H ;
FRIEDRICH, J ;
FUS, I ;
BEYER, T ;
HEIMANN, H ;
HIMER, W .
PHARMACOPSYCHIATRY, 1992, 25 (05) :233-239